Humasis Co. Ltd.

Equities

A205470

KR7205470008

Medical Equipment, Supplies & Distribution

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-12 EDT			5-day change	1st Jan Change
1,926 ^KRW	-0.57%		-0.62%	+2.12%

03-18	Humasis Co. Ltd. announces an Equity Buyback for 17,533,607 shares.	CI
03-18	Humasis Co. Ltd. authorizes a Buyback Plan.	CI

Tranche Update on Humasis Co. Ltd.'s Equity Buyback Plan announced on September 30, 2022.

March 29, 2023 at 01:50 am

From January 1, 2023 to March 29, 2023, the company has repurchased 301,565 shares, representing 0.24% for KRW 5,140.7 million. With this, the company has completed the repurchase of 301,565 shares, representing 0.24% for KRW 5,140.7 million under the buyback announced on September 30, 2022.

Latest news about Humasis Co. Ltd.

Humasis Co. Ltd. announces an Equity Buyback for 17,533,607 shares.	03-18	CI
Humasis Co. Ltd. authorizes a Buyback Plan.	03-17	CI
Tranche Update on Humasis Co. Ltd.'s Equity Buyback Plan announced on February 26, 2024.	03-14	CI
Humasis Co. Ltd.'s Equity Buyback announced on February 26, 2024, has closed with 73,304 shares.	03-13	CI
Humasis Co. Ltd. announces an Equity Buyback for 73,304 shares.	02-26	CI
Humasis Co. Ltd. authorizes a Buyback Plan.	02-24	CI
Tranche Update on Humasis Co. Ltd.'s Equity Buyback Plan announced on May 18, 2023.	23-05-24	CI
Humasis Co. Ltd.'s Equity Buyback announced on May 18, 2023, has closed with 73,300 shares for KRW 185.45 million.	23-05-22	CI
Humasis Co. Ltd. announces an Equity Buyback for 73,300 shares.	23-05-18	CI
Humasis Co. Ltd. authorizes a Buyback Plan.	23-05-17	CI
Humasis Co. Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Tranche Update on Humasis Co. Ltd.'s Equity Buyback Plan announced on September 30, 2022.	23-03-29	CI
Tranche Update on Humasis Co. Ltd.'s Equity Buyback Plan announced on September 30, 2022.	23-03-29	CI
Humasis Co. Ltd.'s Equity Buyback announced on September 30, 2022, has expired with 301,565 shares, representing 0.24% for KRW 5,140.7 million.	23-03-28	CI
7.6% stake in Humasis Co. Ltd. from Cha, Jung Hak, Oh, Min Jung, Oh, Jung Woo and Cha, Bo Yeon.	23-02-08	CI
ArtistCosmetics. Co., Ltd. agreed to acquire 7.6% stake in Humasis Co. Ltd. from Cha, Jung Hak, Oh, Min Jung, Oh, Jung Woo and Cha, Bo Yeon for KRW 65 billion.	23-01-26	CI
Tranche Update on Humasis Co. Ltd.'s Equity Buyback Plan announced on September 30, 2022.	22-12-28	CI
Tranche Update on Humasis Co. Ltd.'s Equity Buyback Plan announced on May 26, 2022.	22-11-25	CI
Humasis Co. Ltd.'s Equity Buyback announced on May 26, 2022, has expired with 1,456,252 shares, representing 2.74% for KRW 20,036.05 million.	22-11-24	CI
Humasis Co. Ltd. announces an Equity Buyback for KRW 20,000 million worth of its shares.	22-09-30	CI
Humasis Co. Ltd. authorizes a Buyback Plan.	22-09-29	CI
Tranche Update on Humasis Co. Ltd.'s Equity Buyback Plan announced on March 16, 2022.	22-09-16	CI
Tranche Update on Humasis Co. Ltd.'s Equity Buyback Plan announced on March 16, 2022.	22-09-16	CI
Humasis Co. Ltd.'s Equity Buyback announced on March 16, 2022, has expired with 706,367 shares, representing 2.07% for KRW 9,992.85 million.	22-09-15	CI
Tranche Update on Humasis Co. Ltd.'s Equity Buyback Plan announced on May 26, 2022.	22-08-25	CI

Chart Humasis Co. Ltd.

Duration

Period

More charts

Company Profile

Humasis Co Ltd is a Korea-based company principally engaged in the manufacture and sale of in vitro diagnostic devices. The Company is engaged in the manufacture and sale of immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, cancer marker test devices and other products. In addition, the Company is engaged in the research and development of biomaterials and other products. The Company sells its products within domestic market and to overseas markets. The Company was established in 2000 and is located in Gunpo-si, Gyeonggi-do, South Korea.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
HUMASIS CO. LTD.	+2.12%	179M
BIOMÉRIEUX	-3.58%	12.37B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-1.48%	8.37B
DIASORIN S.P.A.	+8.70%	5.84B
LANTHEUS HOLDINGS, INC.	+25.61%	5.4B
AUTOBIO DIAGNOSTICS CO., LTD.	-4.58%	4.37B
10X GENOMICS, INC.	-51.80%	3.23B
ANDON HEALTH CO., LTD.	+16.25%	2.8B
MYRIAD GENETICS, INC.	+30.25%	2.26B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-4.08%	1.87B

Diagnostic & Testing Substances